- $1.03m
- $31.39m
- $16.00m
Annual income statement for Biotricity, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.65 | 9.64 | 12.1 | 13.8 | 16 |
| Cost of Revenue | |||||
| Gross Profit | 4.57 | 5.44 | 8.36 | 10.6 | 12.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 26.8 | 25.1 | 20.9 | 16.4 | 14.3 |
| Operating Profit | -19.2 | -15.5 | -8.81 | -2.59 | 1.71 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.1 | -18.7 | -14.1 | -8.42 | -2.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.1 | -18.7 | -14.1 | -8.42 | -2.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.1 | -18.7 | -14.1 | -8.42 | -2.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30.2 | -19.5 | -14.9 | -11.9 | -3.13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.84 | -2.25 | -1.66 | -0.548 | -0.115 |